Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cinchophen is an analgesic drug first synthesized in 1887 and introduced commercially in 1908 primarily for the treatment of gout and arthritis. It belongs to the class of phenylquinolines, organic compounds containing a quinoline moiety substituted with a phenyl group. The drug acts by reducing uric acid buildup, providing relief from gout symptoms and arthritis pain. However, its use in humans was largely discontinued by the 1930s due to serious hepatotoxicity including liver damage, jaundice, hepatitis, and fatal outcomes. Despite this, it remains used in veterinary medicine combined with prednisolone for treating arthritis in animals. It can be administered orally or intravenously. Chemically it is known as 2-phenylquinoline-4-carboxylic acid with formula C16H11NO2 and molar mass approximately 249 g/mol.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cinchophen.